USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Note: This document contains side effect information about cefixime. Some of the dosage forms listed on this page may not apply to the brand name Suprax.
Applies to cefixime: oral capsule, oral powder for suspension, oral tablet, oral tablet chewable
Along with its needed effects, cefixime (the active ingredient contained in Suprax) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking cefixime:
Incidence not known
Some side effects of cefixime may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to cefixime: oral capsule, oral powder for reconstitution, oral tablet, oral tablet chewable
The most commonly reported side effects included gastrointestinal effects, diarrhea, nausea, and/or frequent/loose stools.
Very common (10% or more): Gastrointestinal effects (up to 30%), diarrhea (up to 16%)
Common (1% to 10%): abdominal pain, dyspepsia, flatulence, frequent stools, loose stools, nausea
Uncommon (0.1% to 1%): Vomiting
Very rare (less than 0.01%): Antibiotic-associated colitis
Frequency not reported: Marked diarrhea, moderate diarrhea, severe diarrhea, pseudomembranous colitis
Postmarketing reports: Colitis
Diarrhea more commonly occurred with higher doses. Treatment cessation was occasionally warranted in patients who developed moderate to severe diarrhea. Patients who develop marked diarrhea should discontinue treatment.
Uncommon (0.1% to 1%): Alkaline phosphatase increased, ALT increased, AST increased, liver enzyme increased
Very rare (less than 0.01%): Cholestatic jaundice, hepatitis
Frequency not reported: Blood bilirubin increased, jaundice
Postmarketing reports: Cholestasis, hyperbilirubinemia, liver dysfunction
Uncommon (0.1% to 1%): Rash/skin rash
Rare (0.01% to 0.1%): Pruritus
Very rare (less than 0.01%): Drug rash with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, toxic epidermal necrolysis
Frequency not reported: Erythema multiforme, face edema, urticaria
Encephalopathy included confusion, convulsions, impaired consciousness, and/or movement disorders; beta-lactams predispose patients to the risk of this side effect, especially in cases of overdose or renal dysfunction.
Convulsions occurred with cephalosporins.
Uncommon (0.1% to 1%): Headache
Rare (0.01% to 0.1%): Vertigo
Very rare (less than 0.01%): Psychomotor hyperactivity
Frequency not reported: Convulsions, consciousness impaired, dizziness, encephalopathy, movement disorders
Postmarketing reports: Seizures
Rare (0.01% to 0.1%): Bacterial superinfection, fungal superinfection
Very rare (less than 0.01%): Serum sickness-like reaction/serum sickness
Postmarketing reports: Candidiasis, superinfection
Rare (0.01% to 0.1%): Angioneurotic edema, hypersensitivity
Very rare (less than 0.01%): Anaphylactic shock
Frequency not reported: Anaphylactic reaction/anaphylactoid reaction, angioedema
Postmarketing reports: Allergic reactions, anaphylactic shock, fatal anaphylactic reaction
Rare (0.01% to 0.1%): Mucosal inflammation, pyrexia
Very rare (less than 0.01%): Drug fever
Rare (0.01% to 0.1%): Eosinophilia
Very rare (less than 0.01%): Agranulocytosis, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia
Frequency not reported: Direct positive Coombs test, granulocytopenia, hypereosinophilia, indirect positive Coombs test, neutropenia, thrombocytosis
Postmarketing reports: Aplastic anemia, prothrombin time prolongation
Rare (0.01% to 0.1%): Blood urea increased
Very rare (less than 0.01%): Acute renal failure, blood creatinine increased, interstitial nephritis, tubulointerstitial nephritis
Postmarketing reports: Renal dysfunction, toxic nephropathy, transient blood urea nitrogen elevation (BUN)
Tubulointerstitial nephritis was an underlying pathological condition of acute renal failure.
Rare (0.01% to 0.1%): Anorexia
Frequency not reported: Dyspnea
Frequency not reported: Arthralgia
Frequency not reported: Genital pruritus, vaginitis
Postmarketing reports: Hemorrhage
Postmarketing reports: Elevated lactate dehydrogenase (LDH)
Frequency not reported: Confusion